Where are the adcomms? FDA has scheduled no drug or biologic meetings for 2024 so far

The FDA’s ad­vi­so­ry com­mit­tees of out­side ex­perts typ­i­cal­ly re­view con­tro­ver­sial drug ap­proval de­ci­sions at meet­ings sched­uled months in ad­vance. But the agency’s ad­comm cal­en­dar for 2024 has yet to reg­is­ter a sin­gle meet­ing for ei­ther a drug or a bi­o­log­ic in 2024.

The FDA, which held three ad­comms in Jan­u­ary 2023 for drugs or bi­o­log­ics, did not im­me­di­ate­ly ex­plain if the lag in the cal­en­dar was due to an in­ter­nal change or just the re­sult of the cur­rent PDU­FA cal­en­dar.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.